Florman, Sander <br/><br/>
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.  [electronic resource] 

 -  Clinical transplantation  04 2018 
 - e13225 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1399-0012 
<br/><br/><label>Standard No.: </label>10.1111/ctr.13225  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept--administration & dosage<br/>Black or African American--statistics & numerical data<br/>Cyclosporine--administration & dosage<br/>Ethnicity--statistics & numerical data<br/>Female<br/>Follow-Up Studies<br/>Glomerular Filtration Rate<br/>Graft Rejection--drug therapy<br/>Graft Survival--drug effects<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Incidence<br/>Kidney Failure, Chronic--surgery<br/>Kidney Function Tests<br/>Kidney Transplantation--methods<br/>Male<br/>Middle Aged<br/>Postoperative Complications<br/>Prognosis<br/>Risk Factors<br/>Survival Rate<br/>Time Factors<br/>Transplant Recipients--statistics & numerical data